The use of sputum cell counts to evaluate asthma medications

British Journal of Clinical Pharmacology

Volumn 52, Issue 2, 2001, Pages 121-128

  Parameswaran, Krishnan ^a   Hargreave, Frederick E ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Asthma drugs; Inflammation; Sputum cell counts

Indexed keywords

ALLERGEN; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOKINE; DITHIOTHREITOL; FENOTEROL; FORMOTEROL; HEPARIN; INTERLEUKIN 12; INTERLEUKIN 5; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIDOCAINE; MONOCLONAL ANTIBODY; MONTELUKAST; PLACEBO; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE;

AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CELL COUNT; CELL KINETICS; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; EOSINOPHIL; EOSINOPHILIA; HUMAN; INFLAMMATORY CELL; PRIORITY JOURNAL; REPRODUCIBILITY; SPUTUM EXAMINATION;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CELL COUNT; DRUG MONITORING; HUMANS; LEUKOTRIENE ANTAGONISTS; SPUTUM; THEOPHYLLINE;

EID: 0034819678     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01433.x     Document Type: Article

References (62)

1. Canadian asthma consensus report
2. The British guidelines on asthma management; review and position statement
3. Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma
4. Indices of airway inflammation in induced sputum: Reproducibility and validity of cell and fluid-phase measurements
5. The safety and success rate of sputum induction using a low output ultrasonic nebuliser
6. Methods for sputum induction and analysis of induced sputum: A method for assessing airway inflammation in asthma
7. Induced sputum: Selection method
8. Between-observer repeatability of sputum differential cell counts. Influence of cell viability and squamous cell contamination
9. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation
10. Exacerbations of asthma without sputum eosinophilia
11. Non-eosinophilic corticosteroid unresponsive asthma
12. Sputum in severe exacerbations of asthma: Kinetics of inflammatory indices after prednisone treatment
13. Nonasthmatic chronic cough: No effect of treatment with an inhaled corticosteroid in patients without sputum eosinophilia
14. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis
15. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
16. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma
17. Prednisone dependent asthma: Inflammatory indices in induced sputum
18. Chronic cough with eosinophilic bronchitis and examination for variable airflow obstruction and response to corticosteroid
19. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses
20. Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses
21. Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers
22. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation
23. An inhaled corticosteroid, budesonide, reduces baseline but not allergen-induced increases in bone marrow inflammatory cell progenitors in asthmatic subjects
24. Low- and high-dose fluticasone propionate in asthma: Effects during and after treatment
25. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid
26. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant
27. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma
28. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5-monophosphate in asthmatic patients
29. Regular inhaled beta-agonist treatment in bronchial asthma
30. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects
31. Effects of terbutaline and budesonide on sputum cells and bronchial responsiveness in asthma
32. Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects
33. Effect of salmeterol on airway eosinophils
34. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: A randomized, placebo-controlled trial
35. Treatment of adult asthmatic patients symptomatic on low dose inhaled salmeterol to existing inhaled corticosteroid therapy with increasing dose of inhaled corticosteroids
36. Comparison of addition of salmeterol to inhaled steroids with doubling the dose of inhaled corticosteroids
37. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma
38. Potential masking effects of salmeterol on airway inflammation in asthma
39. The effect of theophylline on blood and sputum eosinophils and ECP in patients with bronchial asthma
40. Suppression of airway inflammation by theophylline in adult bronchial asthma
41. Effect of theophylline withdrawal on airway inflammation in asthma
42. Effect of a 4-week treatment with theophylline on sputum eosinophilia and sputum chemotactic activity in steroid-naive asthmatics
43. Montelukast reduces eosinophilic inflammation in asthma: A randomized, controlled trial
44. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma
45. Effect of pranlukast on bronchial inflammation in patients with asthma
46. Prednisone-dependent asthma: Examination of the anti-inflammatory effects of lidocaine
47. Evaluation of inhaled heparin in asthma: Methodologic challenges
48. Bronchoalveolar lavage in asthma: The effect of disodium cromoglycate (cromolyn) on leukocyte counts, immunoglobulins, and complement
49. Neutrophils in induced sputum arise from central airways
50. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
51. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response
52. Effects of recombinant human interleukin-12 on eosinophils, airway hyperresponsiveness, and the late asthmatic response
53. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: The results of a factor analysis
54. Changes in sputum eosinophils predict loss of asthma control
55. Persistence of sputum eosinophilia in children with controlled asthma when compared with healthy children
56. Induced sputum cell counts: Their usefulness in clinical practice
57. Use of induced sputum to select add-on therapy in persistent asthma
58. Sputum eosinophil count to assess compliance with corticosteroid therapy in asthma
59. Neutrophil infiltration and release of IL-8 in airway mucosa from subjects with grain dust-induced occupational asthma
60. Induced sputum cell counts in healthy adults
61. Repeatability of allergen-induced airway inflammation